Christopher Gottschalk, MD: Long-Term Safety in Preventive Migraine Therapies
July 25th 2019The director of headache medicine and chief of general neurology at Yale Medicine discussed the long-term success the new preventive migraine therapies have shown thus far, and how the lack of safety concerns will improve how they’re utilized.
Christopher Gottschalk, MD: Advantages of Eptinezumab and CGRP Inhibitors
July 14th 2019The director of headache medicine and chief of general neurology at Yale Medicine spoke about the significance of having CGRP inhibitors in migraine treatment, and how eptinezumab fits into the treatment landscape.